{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy+1&page=4", "query": { "condition": "Myotonic Dystrophy 1", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 86, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy+1&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy+1&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:25:21.429Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06204809", "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonic Dystrophy 1" ], "interventions": [ { "name": "PGN-EDODM1 for infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PepGen Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2023-12-12", "completion_date": "2025-10-28", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 7, "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204809" }, { "nct_id": "NCT07630389", "title": "Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy Type 1", "Congenital DM1", "Juvenile DM1", "Childhood DM1" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2023-11-13", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630389" }, { "nct_id": "NCT05224778", "title": "DMCRN-02-001: Assessing Pediatric Endpoints in DM1", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Myotonic Dystrophy", "CDM" ], "interventions": [], "intervention_types": [], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "59 Months", "sex": "ALL", "summary": "Up to 59 Months" }, "enrollment_count": 50, "start_date": "2022-08-24", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 4, "location_summary": "Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05224778" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT03155594", "title": "CGM to Aid Transition From Inpatient to Outpatient", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabete Mellitus" ], "interventions": [ { "name": "Freestyle Libre", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Methodist Medical Center of Illinois", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-05-09", "completion_date": "2017-08-01", "has_results": false, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 1, "location_summary": "Peoria, Illinois", "locations": [ { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155594" }, { "nct_id": "NCT00346255", "title": "BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BB-10901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2013-04-23", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346255" }, { "nct_id": "NCT02251457", "title": "Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonia Congenita", "Paramyotonia Congenita", "Myotonic Dystrophy 1" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02251457" }, { "nct_id": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-Positive Primary Breast Cancer", "Residual Invasive Breast Cancer" ], "interventions": [ { "name": "DS-8201a", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1600, "start_date": "2020-12-04", "completion_date": "2028-06-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 126, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04622319" }, { "nct_id": "NCT07608432", "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy (DMD)", "Muscular Dystrophy, Duchenne", "Muscular Dystrophy (DMD)", "DMD", "Muscular Dystrophies", "Muscular Dystrophy in Children", "Muscular Dystrophy, Duchenne Type", "Muscular Dystrophy, Duchenne and Becker Types", "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)", "Genetic Disease, Inborn", "Genetic Disease, X-Linked", "Congenital, Hereditary, and Neonatal Diseases and Abnormalities", "Neuromuscular Diseases (NMD)" ], "interventions": [ { "name": "Zeleciment Rostudirsen (DYNE-251)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dyne Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "18 Years", "sex": "MALE", "summary": "4 Years to 18 Years · Male only" }, "enrollment_count": 90, "start_date": "2026-06", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 1, "location_summary": "Hillsborough, North Carolina", "locations": [ { "city": "Hillsborough", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07608432" }, { "nct_id": "NCT04620187", "title": "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer", "HER2 Gene Mutation" ], "interventions": [ { "name": "Ado-trastuzumab (T) emtansine (T-DM1)", "type": "DRUG" }, { "name": "Standard of Care Radiotherapy", "type": "RADIATION" }, { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-24", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-07T14:25:21.429Z", "location_count": 13, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 8 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04620187" } ] }